Life Science Report
Insights. Impacts. Imperatives.
Which trends are changing the healthcare system – and what will these trends mean for life and health insurance and the life science industry? See for yourself!
properties.trackTitle
properties.trackSubtitle
Current trends and developments
New ways of working, an ageing society, digitalization, rapid advances in biogenetics and new breakthroughs in medical technology: viewed separately, individual changes and innovations only occasionally appear disruptive.
In fact, just the opposite is the case. We are currently living in an age in which countless advances are taking place simultaneously, accumulating and reinforcing each other. This is changing society, the lives of each and every one of us, and the business environment for companies in the life science industry and in life and health insurance.
What are the main trends? How are they already impacting the future? And how can companies in the health sector respond to these trends? To answer these questions from more than one perspective, experts at Munich Re and Arthur D. Little, a global management consultancy, have pooled their expertise and recommendations in a jointly written Life Science Report. Our common goal: bringing innovations to patients faster and to push the boundaries of insurability.
Insights. Impacts. Imperatives.
The Life Science Report released by Arthur D. Little and Munich Re offers a business-relevant guide for stakeholders in life and health insurance and in the life science industry.
This is reflected in the structure of the report. The focus is on insights, impacts and imperatives on five key topics. Find out more and click through the structure of the report below.
Talking to experts
The Life Science Report is the result of in-depth research and a professional exchange between researchers and practitioners.
Mental health, for instance, is a leading topic. In an expert interview, Prof. Dr. Dr. Florian Holsboer, Director Emeritus of the Max Planck Institute for Psychiatry, and Dr. Alban Senn, Chief Medical Officer at Munich Re, discussed the associated challenges for medicine, pharmacology and the insurance industry.